Company announcement – No. 49 / 2022
Zealand Pharma Hosts Conference Call on November 10 at 4pm CET (10am ET) to Present Third Quarter Results for 2022
Copenhagen, Denmark and Boston, MA, U.S. November 3, 2022 – a Zealand Pharma A/S (CVR-no. 20045078) a biotechnology firm targeted on the invention and growth of modern peptide-based medicines, introduced that it’s going to host a convention name on November 10, 2022 at 4 pm CET (10 am ET) following the announcement of outcomes for the third quarter of 2022.
Presenting in the course of the name might be President and Chief Executive Officer Adam Steensberg, Chief Financial Officer Henriette Wennicke, and Chief Medical Officer David Kendall. The presentation might be adopted by a Q&A session. The convention name might be performed in English.
Telephone dial-in data and a singular private entry PIN might be offered upon registration by way of the next hyperlink, https://register.vevent.com/register/BI2233344c2eff4f40be51448707df4e03.
A dwell audio webcast of the decision, together with an accompanying slide presentation, might be out there by way of the next hyperlink, (*10*) and might be accessible on the Investor part of Zealand’s web site (www.zealandpharma.com/events-cal). A recording of the occasion might be out there on the Investor part of Zealand’s web site after the decision.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology firm targeted on the invention and growth of peptide-based medicines. More than 10 drug candidates invented by Zealand have superior into scientific growth, of which two have reached the market and three candidates are in late-stage growth. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create alternatives for extra sufferers to probably profit from Zealand-invented peptide investigational brokers at present in growth.
Zealand was based in 1998 and headquartered in Copenhagen, Denmark, with a presence within the U.S. that features Boston. For extra details about Zealand’s business and actions, please go to http://www.zealandpharma.com.
Forward-Looking Statement
The above data accommodates forward-looking statements that present Zealand Pharma’s expectations or forecasts of future occasions. Such forward-looking statements are topic to dangers, uncertainties and inaccurate assumptions, which can trigger precise outcomes to vary materially from expectations set forth herein and should trigger all or any of such forward-looking statements to be incorrect. If all or any of such forward-looking statements show to be incorrect, our precise outcomes may differ materially and adversely from these anticipated or implied by such statements. All such forward-looking statements converse solely as of the date of this launch and are based mostly on data out there to Zealand Pharma as of the date of this launch.
Contacts:
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: [email protected]
David Rosen (U.S. Media)
Argot Partners
Email: [email protected]
